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Abstract
Introduction Sunbed use has been significantly associated with increased risk of melanoma and non-melanoma skin
cancer (NMSC), but its relationship with melanoma’s risk factors such as high nevus count, atypical nevi and lentigines is
poorly studied. Euromelanoma is a skin cancer prevention campaign conducted all over Europe. It offers a once-a-year
screening during which participants’ data, including sunbed use and phenotype, are collected via questionnaires.
Objectives To investigate the association of sunbed use with nevus count, atypical nevi, lentigines and suspicion of
skin cancer.
Methods To ensure reliability of the data, we defined inclusion and exclusion criteria for countries’ eligibility for the risk
analysis. Multivariate logistic regression models (including age, gender, education, skin type, family history of melanoma,
personal history of skin cancer, any sun exposure and any sunscreen use) were used to calculate summary odds ratios
(SORs) of each clinical endpoint for ever sunbed use.
Results Overall, 227 888 individuals from 30 countries completed the Euromelanoma questionnaire. After the data
quality check, 16 countries were eligible for the multivariate analysis, for a total of 145 980 participants (64.8% females;
median age 43 years; 62.3% highly educated; 28.5% skin type I–II; 11.0% ever sunbed use). Ever sunbed use was inde-
pendently associated with nevus count >50 [SOR = 1.05 (1.01–1.10)], atypical nevi [SOR = 1.04 (1.00–1.09)], lentigines
[SOR = 1.16 (1.04–1.29)] and suspicion of melanoma [SOR = 1.13 (1.00–1.27)]. Conversely, no significant association
was found between ever sunbed use and suspicion of NMSC [SOR = 1.00 (0.91–1.10)].
Conclusions Indoor tanning is significantly associated with well-recognized risk factors for melanoma (including high
nevus count, presence of atypical nevi and lentigines) as well as suspicion of melanoma within the Euromelanoma scree-
nees. In order to reduce the prevalence of melanoma risk factors, avoidance/discontinuation of sunbed use should
always be encouraged, especially but not exclusively for individuals with high-risk phenotypes.
Received: 14 May 2018; Accepted: 20 September 2018
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Introduction
The use of artificial tanning lamps for cosmetic purposes is
extremely common in developed areas of the world including
Europe.1 This raises concern among health providers and leg-
islators, as sunbed use has been associated with an increased
risk of melanoma and non-melanoma skin cancer (NMSC)
by several studies, summarized in meta-analyses.2–8 Indeed,
the International Agency for Research on Cancer (IARC) cur-
rently regards the whole spectrum of ultraviolet (UV) radia-
tion as well as UV-emitting tanning devices as first-group
carcinogens alongside tobacco smoking and asbestos.9,10 Asso-
ciations between indoor tanning exposure and melanoma’s
risk factors such as high nevus count, atypical nevi and
lentigines have also been suggested, though not extensively
studied up to date.11–19
Euromelanoma is a skin cancer prevention campaign that is
conducted all over Europe since almost two decades.20–22 Its
main goal is to promote awareness of skin cancer among the
general public. Euromelanoma aims therefore to inform and
educate the population as to how to prevent skin cancer by
avoiding modifiable risk factors, and to recognize suspicious
skin lesions by skin self-examination. Moreover, Euromelanoma
offers once-a-year free screenings to the general public, during
which screenees and physicians are requested to complete a
questionnaire enquiring about participants’ socio-demographics,
phenotype, risk factors (including sunbed use) and several clini-
cal findings.
The objective of this study was to investigate the association
of sunbed use with established melanoma’s risk factors such as
high nevus count, presence of atypical nevi and lentigines as well
as with suspected skin cancers detected by dermatologists during
the Euromelanoma screening.
Materials and methods
Euromelanoma campaign and questionnaire
The Euromelanoma campaign was organized annually by the
Euromelanoma Networking Group, under the auspices of the
European Academy of Dermatology and Venereology (EADV)
and the European Association of Dermato-Oncology (EADO).
Every year, a media campaign focusing on particular aspects of
skin cancer prevention was conducted on TV, radio, newspa-
pers/magazines and Internet (www.euromelanoma.org) during
the month of April. The campaign then culminated each year
with the Euromelanoma day (usually in May), during which
free-of-charge skin examinations were offered by both public
and private dermatology clinics in several European countries.
As previously described,20,21 participants were evaluated by
means of the Euromelanoma questionnaire, which was standard-
ized for all participating countries since 2009. The questionnaire
was divided in two sections: the first was to be completed by the
screenees and enquired about their demographics and risk fac-
tors; the second was then filled in by the screening dermatologist
and focused on clinical findings that emerged during the visit.
Questionnaires were sent to the coordinator centre of each
country and data were then entered in a unique database (devel-
oped with Limesurvey version 1.82+), located at the Department
of Dermatology, Universite Libre de Bruxelles, Brussels, Bel-
gium.
Statistical analysis
The variable ‘any sunscreen use’ (no/yes) was created by pooling
together sunscreen use when outdoors for >1 h and sunscreen
use when sunbathing. The variable ‘any sun exposure’ (no/yes)
was created by pooling together outdoor occupation, history of
sunburn and sunny holidays.
Sunbed use was investigated by two questions: ‘Do you use
solarium?’ (possible answers ‘No’, ‘Yes, ≤20 sessions/year’, ‘Yes,
>20 sessions/year’) enquired about current sunbed use; and
‘Number of years using solarium (including in the past only)’
enquired about duration of ever sunbed use. Participants not
reporting current sunbed use but reporting duration of sunbed
use were considered ever users along with those reporting cur-
rent use.
The following clinical variables were used as endpoints: pres-
ence of suspected melanoma, presence of suspected basal cell
carcinoma (BCC), presence of suspected squamous cell carci-
noma (SCC), presence of actinic keratoses (AKs), nevus count,
presence of atypical nevi (defined as nevi with asymmetric, ill-
defined borders, irregular pigmentation and diameter >6 mm)
and presence of lentigines on the back/chest, all categorized as
no/yes variables.
Descriptive statistics, with frequencies, median values and
interquartile ranges, are presented to report the socio-demo-
graphic characteristics of the surveyed population. Percentages
and 95% confidence intervals (CIs) are presented to define the
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frequency of the clinical endpoints in each country. Chi-square
and Fisher’s exact tests were used to determine associations with
clinical endpoints in univariate analysis to select variables to be
included in multivariate analysis.
Multivariate logistic regression models (including age, gen-
der, education, skin type, family history of melanoma, per-
sonal history of skin cancer, any sun exposure and any
sunscreen use) were used to calculate the odds ratio (OR) of
each clinical endpoint for ever sunbed use in each country.
Summary ORs (SORs) of estimates from each country were
then calculated for each clinical endpoint, with 95% CI, and
forest plots were presented with estimates for each country.
Between-country heterogeneities were assessed by Higgins and
Thompson’s I2 statistics,23 which can range from zero to
100% – zero indicating a lack of heterogeneity, that is, that
the ORs are consistent with each other. All statistical tests
were considered significant for P-values ≤0.05. Statistical anal-
yses were carried out using SAS 9.2.
Data quality control: inclusion and exclusion criteria for
countries’ eligibility
Important clinical endpoints of this study were represented
by suspected skin cancers; indeed, if a suspicious lesion was
found during the screening, patients were advised for further
diagnostics and treatment, but follow-up data on diagnosis
were not collected in all countries due to privacy and legisla-
tive issues. Taking into consideration the lack of histopatho-
logical confirmation of suspected lesions, we performed a
strict data quality check by which we formulated two inclu-
sion criteria and two exclusion criteria for countries’ partici-
pation in the multivariate analysis. Inclusion/exclusion criteria
and related explanations are listed below.
Inclusion criterion 1: <15% of missing values for suspected
melanoma and/or suspected BCC and/or suspected SCC.
Missingness can significantly distort the validity of the con-
clusions, by reducing the representativeness of the sample.24
Inclusion criterion 2: <20% adolescents among partici-
pants. Adolescents are likely not to have had enough time to
develop health consequences due to sunbed use, such as
melanoma; indeed, a previous investigation showed an
increased risk of melanoma associated with sunbed use rang-
ing from 19% (non-significant) among adolescents to 49%
and 61% (both significant) among 30–39 and 40–49 year
olds.25
Exclusion criterion 1: >10% of adolescents diagnosed with
AKs. Estimates from these countries were judged unreliable, as
AKs are extremely rare among adolescents.26
Exclusion criterion 2: >20% of subjects with atypical nevi
considered to have also a suspected melanoma. Probably, in
these countries, atypical nevi were erroneously considered as
suspected melanomas and therefore excised, although nevi and
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Results
Thirty countries took part in the Euromelanoma campaigns
2009–2014, for a total of 227 888 participants. Details of coun-
tries’ participation over time are provided in Table S1.
Fourteen countries were not eligible for the multivariate sta-
tistical analysis, as they failed the data quality check. In particu-
lar, seven countries could not be considered as they did not
satisfy inclusion criteria: Germany, Latvia, Russia, Spain, Turkey
and Ukraine did not meet inclusion criterion 1 (they all had
>15% of missing values for suspected melanoma and/or sus-
pected BCC and/or suspected SCC; Table 1); Romania did not
meet inclusion criterion 2 (30.2% of participants were adoles-
cents; Table S2). Moreover, seven other countries had to be
subsequently removed as they fulfilled exclusion criteria: Mol-
dova met exclusion criterion 1, as Russia would have done too
had it been included (12.5% and 13.1% of adolescents diagnosed
with AKs, respectively; Table S3); Croatia, Cyprus, Denmark,
Lithuania, Malta and Serbia met exclusion criterion 2 (>20% of
subjects with atypical nevi considered to have also a suspected
melanoma), as Germany would have done too had it been
included (Table 2).
Consequently, 16 countries were included in the main analy-
sis, for a total of 145 980 participants. Details about the demo-
graphic, phenotypic and sunbed variables for each eligible
country are presented in Table S4. Overall, 64.8% were females
and 35.2% males; median age was 43 years (interquartile range
31–59, 6.9% adolescents); 62.3% attained high education and
37.7% low education; 28.5% reported skin type I–II and 71.5%
skin type III–VI. Ever use of sunbed was reported by 11.0% of
those who responded to the sunbed questions (15 650/142 204).
Melanoma suspicion rate varied from 1.2% (Portugal) to
7.0% (Slovenia) and was higher than BCC suspicion rate in 6 of
16 (37.5%) countries and than SCC suspicion rate in 16 of 16
(100%) countries (Table 3).
The summary estimate suggested a significant, independent
association between suspected melanoma and ever sunbed expo-
sure, with between-country heterogeneity [SOR = 1.13 (1.00–
1.27), I2 = 11%] (Fig. 1a).
The SOR of suspected NMSC (pooling together suspected
BCC, suspected SCC and AKs) for ever sunbed use was 1.00
(0.91–1.10), without between-country heterogeneity (I2 = 0%;
Fig. 1b). Models assessing the association of ever sunbed use
with suspected NMSC combined in different ways (including
suspected BCC and suspected SCC but excluding AKs or includ-
ing suspected BCC alone, suspected SCC alone or AKs alone)
produced similar results (data not shown).
Furthermore, the summary estimates suggested significant,
independent associations between ever sunbed use and: nae-
vus count >50 [SOR = 1.05 (1.01–1.10), I2 = 0%] (Fig. 2);
presence of atypical nevi [SOR = 1.04 (1.00–1.09), I2 = 0%]
(Fig. 3); and lentigines, [SOR = 1.16 (1.05–1.29), I2 = 68%]
(Fig. 4).
Estimates for dose–response effect were not available due to
low numbers of intermediate and high sunbed users (data not
shown).
Discussion
The use of sunbeds is currently permitted in Europe, but restric-
tions related to age and skin type of users have been put in place
in several European countries. The European legislation for sun-
beds, which falls within the Low Voltage Directive (2014/35/EU)
for electrical equipment, sets the limits for UV radiation emis-
sion to 300 mW/m2 of total effective irradiance (harmonized
European standard EN 60335-2-27:2013). Recently, though, arti-
ficial tanning has been declared unsafe by the European
Table 2 Prevalence of suspected melanoma according to atypical
nevi status for each participating country
Prevalence of
suspected melanoma




in the presence of
atypical nevi
Belgium 70 (0.9) 167 (10.3)
Bosnia-
Herzegovina
60 (1.2) 91 (5.3)
Croatia 107 (3.3) 603 (46.0)
Cyprus 2 (7.7) 2 (22.2)
Czech Republic 120 (0.9) 507 (18.6)
Denmark 28 (1.5) 54 (23.9)
Estonia 25 (2.4) 18 (6.6)
Georgia 25 (1.1) 29 (6.2)
Germany 151 (3.4) 367 (20.1)
Greece 172 (0.8) 399 (5.3)
Hungary 71 (0.8) 268 (9.5)
Ireland 6 (2.1) 3 (18.8)
Italy 10 (0.4) 52 (10.0)
Latvia 11 (0.7) 11 (3.2)
Lithuania 28 (0.7) 209 (21.3)
Macedonia
(FYROM)
28 (2.9) 26 (7.9)
Malta 3 (0.8) 11 (22.9)
Moldova 5 (15.6) 3 (12.5)
Norway 18 (1.8) 40 (18.7)
Poland 25 (0.5) 94 (6.0)
Portugal 35 (0.6) 53 (3.9)
Romania 7 (0.3) 11 (2.1)
Russia 122 (1.6) 212 (11.8)
Serbia 96 (1.6) 806 (41.6)
Slovenia 11 (2.0) 45 (18.5)
Spain 15 (0.5) 42 (6.0)
Sweden 234 (1.7) 335 (15.8)
Switzerland 248 (1.7) 343 (12.7)
Turkey 7 (0.7) 34 (9.7)
Ukraine 122 (1.2) 126 (5.9)
N (%) shown in each box. Countries in which>20% of subjects with atypi-
cal nevi were considered to have also a suspected melanoma are high-
lighted in bold.
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Commission, whose Scientific Committee on Health, Environ-
mental and Emerging Risks (SCHEER) stated that there is no
safe limit for exposure to UV radiation from sunbeds.31 To cor-
roborate the official opinion of the SCHEER, we decided to
exploit the Euromelanoma database, which included informa-
tion about a large number of participants from 30 countries.
Our goal was to investigate the association of sunbed use with
well-established risk factors, namely suspected skin cancer, nevus
count, presence of atypical nevi and lentigines.
Our multivariate analysis found a significant association
between ever exposure to sunbeds and suspected melanoma,
after adjustment for potential confounders. Although it was
impossible in this study to ascertain whether suspected mela-
nomas were confirmed as such by histopathology, this result
appears to confirm the current evidence that sunbed use
increases melanoma risk. In particular, our estimate was con-
sistent with those found in previous meta-analyses assessing
melanoma risk associated with ever using sunbeds: 15% by
the IARC,2 16% (10% for Europe alone) by Colantonio
et al.,6 19% by Burgard et al.,7 20% by Boniol et al.,4 22%
by Hirst et al.,3 and 25% by Gallagher et al.8 Like others
before,6,32 Burgard and co-workers recently raised criticisms
about the association between sunbed use and melanoma
risk, including limitations of individual studies (selection and
recall biases, typical of case-control studies; non-adjustment
for certain confounders) and lack of large randomized or
prospective studies (which in the case of sunbeds would be
unethical or too costly, respectively). Yet, they found similar
results in their meta-analysis, even using a different statistical
method.7 In spite of their scepticism then, we believe their
recent meta-analysis actually adds to the body of evidence
suggesting that sunbed use should be strongly discouraged in
order to reduce melanoma risk.
Although the relationship between sunbed use and increased
risk of NMSC has been established by previous meta-analyses,2–5
unfortunately, we were not able to confirm this association. Pos-
sible explanations include the lack of histopathological confir-
mation of the suspected NMSC and the relatively young age of
the screenees (median 43 years), which could suggest that par-
ticipants did not have sufficient time to develop NMSC – which
usually occurs later in life than melanoma.33 This is corrobo-
rated by the fact that in the present study, NMSC was suspected
less than melanoma in multiple countries, in spite of NMSC
being much more common than melanoma in epidemiological
investigations.34–37
We found a significant association between ever sunbed use
and lentigines after adjustment for potential confounders,
including sun exposure and sunscreen use. This confirms previ-
ous case reports of lentigines occurring after sunbed expo-
sure.14–19 Interestingly, these observations reported that the
lentigines induced by artificial tanning (so-called ‘sunbed lentigi-
nes’) have more worrisome pathologic and ultra-structural fea-
tures than common solar lentigines, such as the presence of
melanocytic nuclear atypia and abnormally clumped, pleomor-
phic melanosomes. Moreover, excised ‘sunbed lentigines’ lacked
solar elastosis, which is instead typical of common solar







Suspected AKs Nevus count
>50
Atypical nevi ≥1 Solar lentigos
% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Belgium 2.5 2.2–2.9 2.8 2.5–3.2 0.3 0.2–0.5 7.6 7.1–8.2 14.0 13.3–14.7 17.3 16.6–18.1 44.1 43.1–45.1
Bosnia-
Herzegovina
2.2 1.9–2.6 4.9 4.4–5.5 0.7 0.5–0.9 12.3 11.5–13.1 6.2 5.7–6.8 24.8 23.8–25.8 41.1 39.9–42.3
Czech Republic 3.8 3.5–4.1 1.9 1.7–2.1 0.2 0.2–0.3 7.5 7.1–7.9 5.4 5.1–5.8 16.3 15.7–16.9 16.4 15.9–17.0
Estonia 3.3 2.4–4.4 2.7 1.9–3.8 0.2 0.1–0.7 4.2 3.2–5.4 7.9 6.5–9.5 20.8 18.7–23.2 36.8 34.0–39.8
Georgia 2.0 1.5–2.6 3.4 2.7–4.1 0.4 0.2–0.7 7.3 6.4–8.4 5.5 4.7–6.5 17.5 16.1–19.0 12.2 11.0–13.5
Greece 1.9 1.8–2.1 1.6 1.4–1.7 0.4 0.3–0.4 6.0 5.7–6.3 11.8 11.4–12.1 26.1 25.7–26.6 32.5 32.0–33.0
Hungary 2.9 2.7–3.3 3.1 2.8–3.4 0.4 0.3–0.5 11.4 10.9–12.0 8.9 8.4–9.4 23.8 23.1–24.6 37.3 36.4–38.1
Ireland 3.4 1.7–5.9 3.1 1.5–5.6 0.3 0.0–1.7 14.8 11.1–19.2 0.9 0.2–2.6 5.4 3.2–8.5 21.7 17.2–26.6
Italy 2.1 1.6–2.7 2.8 2.3–3.4 0.3 0.1–0.5 7.6 6.7–8.7 7.9 7.0–8.9 18.0 16.7–19.5 48.5 46.7–50.3
Macedonia
(FYROM)
4.2 3.2–5.4 8.7 7.2–10.3 1.6 1.0–2.5 22.8 20.6–25.2 8.8 7.4–10.5 25.5 23.2–28.0 44.5 41.8–47.3
Norway 4.8 3.7–6.2 4.2 3.1–5.4 0.2 0.0–0.6 6.9 5.6–8.5 17.5 15.5–19.7 18.8 16.7–21.1 32.9 30.3–35.5
Poland 1.8 1.5–2.1 3.2 2.8–3.6 0.4 0.2–0.5 10.4 9.7–11.1 11.8 11.1–12.5 26.7 25.7–27.8 18.6 17.7–19.5
Portugal 1.2 1.0–1.5 2.9 2.5–3.3 0.4 0.2–0.5 5.0 4.6–5.6 7.8 7.2–8.4 19.0 18.1–19.9 34.2 33.1–35.3
Slovenia 7.0 5.3–9.0 2.2 1.3–3.5 0.6 0.2–1.5 4.5 3.2–6.2 16.8 14.3–19.6 30.4 27.2–33.7 49.6 46.1–53.1
Sweden 3.6 3.3–3.9 6.5 6.1–6.9 0.7 0.6–0.8 11.3 10.8–11.8 10.2 9.8–10.7 13.7 13.2–14.3 37.5 36.8–38.3
Switzerland 3.5 3.2–3.7 4.4 4.1–4.7 0.9 0.8–1.1 12.8 12.3–13.3 14.5 13.9–15.1 16.1 15.6–16.6 34.8 34.1–35.5
AK, actinic keratosis; BCC, basal cell carcinoma; CI, confidence interval; FYROM, Former Yugoslav Republic of Macedonia; SCC, squamous cell
carcinoma.
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Figure 1 Forest plots of association of suspected skin cancer with ever use of sunbeds. All odds ratios are adjusted for age, gender,
education, skin type, family history of melanoma, personal history of skin cancer, any sun exposure and any sunscreen use. FYROM, For-
mer Yugoslav Republic of Macedonia. A. Suspected melanoma. Heterogeneity I2 = 11% for all countries. 1In order to calculate the odds
ratio for Georgia, the model for this country was not adjusted for age, skin type and personal history of skin cancer, due to frequency of
suspected melanoma being too low in exposed individuals. 2A sensitivity analysis for Ireland, the only country with a considerable amount
of missing data on sunbed use (20.3%, Table S2) found that the odds ratio of suspected melanoma associated with the missing values
was similar to the odds ratio for exposed individuals [6.31 (0.74–53.71) and 6.27 (0.69–57.27), respectively]. B. Non-melanoma skin can-
cer (NMSC). Heterogeneity I2 = 0% for all countries. 1The odds ratio for Georgia was not available, due to frequency of suspected NMSC
being too low in exposed individuals
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Relative risk (95% CI)
0.6 0.8 1.0 2.0 3.0 4.0
Figure 2 Forest plot of association of high nevus count (>50 nevi) with ever use of sunbeds. Heterogeneity I2 = 0% for all countries. All
odds ratios are adjusted for age, gender, education, skin type, family history of melanoma, personal history of skin cancer, any sun expo-
sure and any sunscreen use. FYROM, Former Yugoslav Republic of Macedonia. 1The odds ratio for Ireland was not available, due to fre-




















Relative risk (95% CI)
0.3 0.6 0.8 1.0 2.0 3.0 4.0
Figure 3 Forest plot of association of ≥1 atypical nevus with ever use of sunbeds. Heterogeneity I2 = 0% for all countries. All odds ratios
are adjusted for age, gender, education, skin type, family history of melanoma, personal history of skin cancer, any sun exposure and any
sunscreen use. FYROM, Former Yugoslav Republic of Macedonia.
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lentigines;38 this suggests an acute phenomenon rather than a
chronic one, consistent with excessive UV exposure resulting
from indoor tanning.
The potential of sunbed exposure to cause melanocytic atypia
might explain the significant, though small association of ever
sunbed use with atypical nevi in our multivariate analysis. In
1989, Roth et al.16 described the case of a woman developing sev-
eral dysplastic junctional nevi after an extended period of UVA
tanning booth use. To our knowledge, the present study provides
the first significant association between ever use of sunbeds and
presence of atypical nevi in a large multivariate analysis. Evi-
dently, this result is of utmost importance as atypical nevi repre-
sent a significant risk factor for melanoma development.39
Exposure to solar UV radiation has been associated with high
nevus count by a number of investigations.40–58 The question
arises as to whether exposure to UV radiation coming from sun-
beds is also associated with high nevus count. Recently, Little
and Lloyd observed that patients with a self-reported history of
sunbed use displayed an increased frequency of multiple junc-
tional nevi located on the buttocks, an area usually protected
from sun exposure but not from tanning bed exposure.13 Previ-
ously, Gellen et al.11 reported in a large sample of Hungarian
students that sunbed users were twice as likely to have >20 nevi
as compared to non-users, after adjustment for skin colour, sun-
bathing and sunburn. Li et al.12 found a significant, independent
association between increasing number of annual sunbed
sessions and higher nevus count in a large cohort of women.
Our results corroborate these data by showing a significant asso-
ciation of sunbed ever use with high nevus count (>50 nevi),
after controlling for any type of sun exposure and other con-
founders. Although this study was not designed to assess
whether sunbed use increases the number of nevi and although
we cannot exclude with absolute certainty that some solar lentig-
ines were misdiagnosed as melanocytic nevi during the Eurome-
lanoma screening, we believe this result is highly important
because it suggests that sunbed use might possibly increase the
number of nevi – and therefore the risk of melanoma39,59,60 –
independently from sun exposure. At any rate, individuals with
high nevus count and/or atypical nevi should be particularly dis-
couraged to use sunbeds because of a possible multiplicative
effect of high nevus count, atypical nevi and indoor tanning on
melanoma risk. Indeed, it was suggested that the negative impact
of sunbed exposure on melanoma risk is generally greater in
individuals with high-risk phenotypes.25
The obvious limitation of this study was that two important
clinical endpoints (melanoma and NMSC) were represented by
suspected rather than histopathologically confirmed lesions.
However, we performed a strict data quality control (that forced
us to exclude data of 14 countries from the main analysis) to
ensure the reliability of our data; the fact that we obtained a
SOR for suspected melanoma similar to the risk estimates
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Figure 4 Forest plot of association of lentigines on back/chest with ever use of sunbeds. Heterogeneity I2 = 68% for all countries. All
odds ratios are adjusted for age, gender, education, skin type, family history of melanoma, personal history of skin cancer, any sun expo-
sure and any sunscreen use. FYROM, Former Yugoslav Republic of Macedonia.
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meta-analyses supports the validity of our results. Another limi-
tation is that the study was not population based but instead
included participants self-attending a skin cancer screening
event: therefore, a selection bias (either towards a more respon-
sible or irresponsible population as for indoor tanning practices;
or towards more aware participants as for the presence of sus-
pected lesions) as well as a desirability bias [under-reporting of a
‘bad habit’ (sunbed use) to please doctors] cannot be excluded.
As a consequence, one might expect a high prevalence of risk
factors among the study participants, who may be more likely to
attend if they have noticed a suspicious lesion on their body or if
they have used a sunbed in the past and are worried about skin
cancer risk. However, if over-reporting of sunbed use by subjects
aware of the risk may have rendered the association with the
clinical endpoints stronger, on the other hand, under-reporting
of sunbed use could have influenced the results towards a weaker
association, thus producing a counterbalance of the above-men-
tioned limitations. A further limitation is that the study was ret-
rospective, therefore, a recall bias cannot be ruled out.61 The
strengths of the study were the extremely large sample size, the
use of a standardized questionnaire in all participating countries,
the strict control of the quality of the data and the thorough
multivariate analysis that included many potential confounders.
In conclusion, we presented a large, comprehensive European
investigation about multiple skin cancer risk factors connected
to sunbed use among participants in the Euromelanoma cam-
paign. This study indicates that indoor tanning is associated with
important risk factors for melanoma such as high nevus count,
presence of atypical nevi and lentigines, as well as suspicion of
melanoma. In order to reduce the prevalence of melanoma risk
factors, avoidance or discontinuation of sunbed exposure should
always be encouraged, especially but not exclusively in individu-
als with high-risk phenotypes such as high nevus count and
atypical nevi.
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